Study links arm/hand swelling to number of lymph nodes removed during breast cancer surgeryApril 24, 2009In older breast cancer survivors, the number of lymph nodes removed during surgery and the presence of cancer in the lymph nodes were the two factors most directly linked to the development of lymphedema, swelling of the arm and hand, according to a study from the Medical College of Wisconsin's Center for Patient Care and Outcomes Research in Milwaukee, Wisconsin. "Lymphedema causes physical discomfort and disability, as well as a cosmetic deformity which can lead to anxiety, depression and emotional distress that can affect a woman's activities of daily living and quality of life," says lead author Tina Yen, M.D., M.S., a Medical College of Wisconsin surgical oncologist who practices at Froedtert Hospital, a major hospital affiliate. "For these reasons, lymphedema is probably the most feared complication among breast cancer survivors. A better understanding of its risk factors is needed to help improve outcomes." The study appears online, in advance of publication in the April issue of Annals of Surgical Oncology. It is significant because there are few large, population-based studies on this topic looking at long-term outcomes from more than one institution, and much of the existing literature was written 20-30 years ago, when more extensive surgeries to the breast and armpit (axilla) were performed and use of radiation therapy to the armpit was more common. The researchers conducted three phone surveys between 2005 and 2007 among 1,338 community-dwelling women, ages 65-89 years, who were identified by Medicare claims as having undergone initial breast cancer surgery in 2003. These 1,338 women were treated by 707 surgeons. Four years after surgery, 14 percent self-reported having lymphedema. Women who developed lymphedema were more likely to have more extensive disease, have undergone more extensive surgery and received chemotherapy. However, after controlling for a woman's age, tumor size, type of surgery, other therapies and surgeon volume, the removal of more than five lymph nodes and the presence of cancer in the lymph nodes were the only two factors that predicted a risk for lymphedema. Most importantly, the number of lymph nodes removed is more predictive of the risk for lymphedema rather than the type of axillary surgery performed (sentinel lymph node biopsy versus axillary node dissection). If no lymph nodes were removed, the risk for lymphedema was 4.7 percent. Removal of up to five lymph nodes did not increase the risk of lymphedema, when compared to the removal of no lymph nodes. However, the removal of between six and 15 lymph nodes increased that risk five-fold, and removal of 16 or more lymph nodes increased the risk of developing lymphedema by more than ten-fold. Given these findings, all women undergoing any axillary surgery should still be counseled on their risk for lymphedema, although this risk may be minimal for women who have fewer than five lymph nodes removed. Medical College of Wisconsin |
|||||||||||||||||||||
| Related Lymph Nodes Current Events and Lymph Nodes News Articles Hundreds of genes distinguish patients likely to survive advanced melanoma Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. Angiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases. Cell study explains why younger people more at risk of vCJD Specific cells within the immune system could help explain why younger people are more susceptible to variant CJD, scientists believe. Genes signal late-stage laryngeal cancer, poorer outcome Researchers at Henry Ford Hospital have identified tumor-suppressing genes that may provide a more accurate diagnosis of disease stage and survival for laryngeal cancer patients than current standards. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness. Study finds 231 new genes associated with head and neck cancer A Henry Ford Hospital study has identified 231 new genes associated with head and neck cancer, one of the most deadly cancers responsible for 2.1 percent of all cancer deaths in the United States. Prostate cancer gives a new outlook on life Men who have prostate cancer often feel quite healthy, but the diagnosis still gives them a whole new outlook on life. Once they have learned to live with their cancer, they choose to focus on valuable relationships and appreciate the little things in life, shows a dissertation thesis from the Sahlgrenska Academy. Pitt researchers net $5 million from NIH to explore better ways to grow cells for regenerative medicine Regenerative medicine researchers at the University of Pittsburgh received two grants totaling more than $5 million from the National Institutes of Health (NIH) to explore new methods for cultivating replacement cells from existing tissues and organs. Ultrasound can predict tumor burden and survival in melanoma patients Researchers have shown for the first time that patterns of ultrasound signals can be used to identify whether or not cancer has started to spread in melanoma patients, and to what extent. The discovery enables doctors to decide on how much surgery, if any, is required and to predict the patient's probable survival. Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take exemestane or tamoxifen do significantly better than patients who start to take one or other drug (or tamoxifen followed exemestane) but then stop. More Lymph Nodes Current Events and Lymph Nodes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||